News | November 19, 2022
Vivimed Labs Q2 FY2023 consolidated loss at Rs. 22.03 Cr
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
The product is expected to be launched by Q4 FY23.
The approval further strengthens the Potassium Chloride franchise for the company.
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Strand’s new offering will help people better understand and manage diseases through genomic sequencing
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Prime Minister Narendra Modi attended an event marking the 100th robotic-assisted surgical system installation at U. N. Mehta Institute of Cardiology, Ahmedabad.
Subscribe To Our Newsletter & Stay Updated
